The global Cardiovascular Medical Devices market and offers an in-depth analysis based on geographic region, country, company, type and application. At the forefront of the market are prominent players like [Abbott Laboratories, Cook medical, Nipro, Lepu Medical, B. Braun] who are actively adopting various strategies to increase their market share and strengthen their position in […]
Category Archives: Cardiovascular
06
Sep
Sep
Deep in the recesses of the gut, they wait, ready to devour whatever comes their way. The microbes that live in the human intestines are not picky; their food is our food. But what we decide to eat — whether a greasy cheeseburger or a beet salad — determines not just the microbes’ health but […]
The recently published “Cardiovascular Medical Devices Market” report from Absolute Reports offers an extensive overview of the industry. It encompasses a range of dimensions, including end-user applications(Hospitals, Clinics, Others ), types (Cardiac Rhythm Management Devices, Interventional Cardiac Devices, Cardiac Prosthetic Devices, Others ), geographical regions, and worldwide projections spanning from 2023 to 2029. This executive […]
To reshape graduate education as well as research and development to better serve local, national, regional, and global sustainable development. Shenzhen, Guangdong, China Tsinghua Shenzhen International Graduate School
06
Sep
Sep
DALLAS – Sept. 06, 2023 – Although hundreds of thousands of patients with atherosclerotic cardiovascular disease (ASCVD) are eligible for high-intensity statin therapy, most are not using the drugs, UT Southwestern Medical Center researchers report. The findings, published in Circulation: Cardiovascular Quality and Outcomes, reveal a wide gap between evidence-based guidelines for the medication and medical practice, […]
06
Sep
Sep
September 06, 2023 2 min read Source/Disclosures Published by: Disclosures: Okazaki and Daugirdas report no relevant financial disclosures. Please see the study for all other authors’ relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles […]
06
Sep
Sep
Food additive emulsifiers were individually associated with modest increases in cardiovascular disease (CVD) in a large French epidemiological cohort, researchers found. Various types of emulsifiers — widely used to keep oils and water mixed together and prolong the shelf-life of processed foods — were positively associated with higher risks of CVD and coronary heart disease […]
Cardiovascular
Mount Sinai Announces Partnership With the Brazilian Clinical Research Institute to Advance Cardiovascular Disease Research and Medical Education
06
Sep
Sep
Newswise — (New York, NY – September 6, 2023) – The Icahn School of Medicine at Mount Sinai announced today that it has signed a memorandum of understanding with the Brazilian Clinical Research Institute (BCRI) to focus on advancing cardiovascular disease research, innovation, and medical education. “This partnership is part of a broader initiative to […]
Cardiovascular
Food additive emulsifiers and risk of cardiovascular disease in the NutriNet-Santé cohort: prospective cohort study
06
Sep
Sep
Abstract Objective To assess the associations between exposure to food additive emulsifiers and risk of cardiovascular disease (CVD). Design Prospective cohort study. Setting French NutriNet-Santé study, 2009-21. Participants 95 442 adults (>18 years) without prevalent CVD who completed at least three 24 hour dietary records during the first two years of follow-up. Main outcome measures Associations […]
Cardiovascular
Long-term efficacy and safety of early alogliptin initiation in subjects with type 2 diabetes: an extension of the SPEAD-A study
05
Sep
Sep
Abstract We previously reported in the study of preventive effects of alogliptin on diabetic atherosclerosis (SPEAD-A) that alogliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, attenuated the progression of carotid atherosclerosis in subjects with type 2 diabetes and no history of cardiovascular disease. This extension study of the SPEAD-A trial investigated whether early alogliptin initiation improved long-term […]